AVI CO 004

Drug Profile

AVI CO 004

Alternative Names: AVI-CO-004

Latest Information Update: 08 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Avixgen
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 09 Mar 2017 Avixgen initiates enrolment in a phase I trial In Volunteers in South Korea (KCT0002279)
  • 19 Dec 2016 Avixgen completes a phase I trial in HIV-1 infections (In volunteers) in South Korea (KCT0002005) prior to December 2016
  • 01 Aug 2016 Phase-I clinical trials in (In volunteers) HIV-1 infections in South Korea (unspecified route) (KCT0002005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top